CD24 and cancer: MSC-Exos showed a significant decrease in the number of CSCs as it decreased the ratio of expression of CD44 + /CD24- cells from an average of 10.5% in the control to an average of 4.8% of the cells in the total amount of the cell line with almost no cytotoxicity which makes exosomes a possible cancer treatment in the future that has nearly no side effects.